A Study to Evaluate the Safety and Efficacy of Artemisinin- a Herbal Supplement on COVID-19 Subjects

The study will involve screening (Day 1), treatment period of up to maximum 28 days till end of study. The investigator shall make every effort to follow the schedule of study assessments and procedures. A window period of 1 day will be allowed for assessments post randomization. Screening Upon obtaining the written informed consent the subjects will be screened to confirm the eligibility for participating in this study. If RT PCR result is available for the subject then screening and baseline (randomization) activity will be on the same day. As per the Investigator discretion, the subjects meeting the criteria will be hospitalized for the first cycle of treatment Treatment period Subjects will receive investigational product and SOC after randomization as per protocol. Subject's compliance with the study treatment regimen of Artemisinin one (1) capsule a day for five (5) days, will be assessed during treatment period. Subjects receiving at least one dose of study treatment will be included in the safety analysis. Efficacy analysis will be conducted in completers (subjects who have completed at least 5 consecutive days of dosing in either arm) The first cycle of the study drug treatment will be given in the hospital, for which the subjects have to be hospitalized till Day 5, unless prolongation of hospital stay is necessary as per the investigator. On day 14, telephonic follow up is done for subjects discharged after Day 5. For Day 28 visit all subjects will visit the hospital to complete the End of Study activities.

Inclusion criteria

• Male or female subjects of ≥18 to 60 years of age both inclusive
• Subjects willing to give informed consent and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures
• Confirmed case of COVID-19 infection by RT-PCR and mild and moderate (without oxygen therapy or assisted ventilation) cases of COVID-19. Scores of 2-4 on the WHO Clinical Progression Scale
• Time interval between symptoms onset and randomization of no more than 7 days
• One or more of the following symptoms:

Fever Cough Sore throat Headache Nasal congestion Malaise Diarrhea Loss of smell Loss of taste

• Male and female subjects of childbearing potential must agree to use a highly effective method of contraception throughout the study and for at least 30 days after the last dose of assigned treatment. A subject is of childbearing potential if, in the opinion of the investigator, he/she is biologically capable of having children and is sexually active.

Exclusion criteria

• Subjects with history of severe infections (pneumonia, septicemia, etc.), severe cardiac or pulmonary diseases, or received immunosuppressive therapy or other investigational drugs within the previous 30 days of screening
• Known or suspected hypersensitivity to Artemisinin
• Women of child bearing potential who are currently pregnant, lactating or who are not willing to use contraception during the entire duration of the study
• Men who are unwilling to use contraception while receiving investigational product
• Subjects with history of severe disease other than COVID-19 which is expected to prevent compliance with the present protocol
• Subjects with history of severe renal and hepatic impairment. (creatine ≥2 mg/dl; liver enzymes and bilirubin 2.5 times ULN; alkaline phosphatase 1.5 times ULN)
• Recent treatment with Artemisinin or Artemisinin based antimalarials in the past 7 days
• Known history of failure to control systemic fungal, bacterial or viral infection
• Patients with the history of following co-morbidities: diabetes, hypertension with or without cardiac symptoms, morbid obesity with diabetes and/or hypertension or any other metabolic syndrome
• Subjects with known human immunodeficiency virus (HIV) or hepatitis B or C classes of active viral infection
• Have a history of neurological or psychiatric disorders, including epilepsy or dementia
• Subjects for whom ventilator support is required at screening
• Patients not willing to stay in hospital for 5 days of isolation following diagnosis of Covid-19
• Subjects not willing to give their informed consent to participate in the clinical trial
• According to the investigator judgment there are concomitant diseases with a serious safety hazard or affect the subject
• Using other experimental drugs or participating in other clinical trials in the prior one month